6
项与 Anti-CD19 CAR-T therapy(Wuhan Si'an Medical Technology) 相关的临床试验Efficacy and Safety of Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma:a Single-center, Open-label, Pragmatic Clinical Trial
This is a single-center, open-label and pragmatic clinical trial to evaluate the primary efficacy and safety of anti-CD19 chimeric antigen receptor (CAR)-modified T cells (CART-CD19) with concurrent BTK inhibitor in patients with relapsed or refractory B cell lymphoma
Late Effects and Follow up after pediatric hematological stem cell transplantation and cell therapy (LEEF)
Treatment of Relapsed or Refractory B-cell Malignancies by Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cells
This is a single arm, open-label study to evaluate the safety and efficacy of humanized anti-CD19 CAR-T cells in patients with relapsed or refractory B cell Malignancies.
100 项与 Anti-CD19 CAR-T therapy(Wuhan Si'an Medical Technology) 相关的临床结果
100 项与 Anti-CD19 CAR-T therapy(Wuhan Si'an Medical Technology) 相关的转化医学
100 项与 Anti-CD19 CAR-T therapy(Wuhan Si'an Medical Technology) 相关的专利(医药)
100 项与 Anti-CD19 CAR-T therapy(Wuhan Si'an Medical Technology) 相关的药物交易